Neuropathy cell therapy offers meaningful value for patients with moderate-to-severe diabetic or painful neuropathy refractory to conventional pharmacotherapy (gabapentin, pregabalin) and lifestyle modification. Cost (€4,500–7,000 per infusion) is reasonable compared to lifelong neuropathic medication (€100–300/month) and disability costs. Response probability (~50–60%) justifies consideration for motivated patients with significant pain or functional impairment. Limitations: durability is uncertain, requiring possible re-treatment; complete sensory restoration is rare; and advanced, longstanding neuropathy with severe axonal loss may respond poorly. Best-fit candidates are age 40–70 with diabetes or known neuropathy aetiology, moderate-to-severe symptoms, failed or intolerant to conventional drugs, and realistic expectations of partial, gradual pain reduction without complete functional restoration.
Peripheral neuropathy encompasses diverse conditions—diabetic, idiopathic, chemotherapy-induced, ischaemic—characterised by progressive nerve fibre loss, demyelination, and sensorimotor dysfunction. Stem cell therapies exploit multiple pathways: placental mesenchymal stem cells (MSCs) secrete neurotrophic factors (NGF, GDNF, VEGF) that promote nerve regeneration and angiogenesis; neurogenic cells differentiate into functional neurons to replace damaged fibres; exosomes deliver growth factor cargo directly into affected peripheral tissues. The rationale combines neuroprotection (halting further degeneration), neuroregenerative repair (sprouting of surviving axons), and vascular restoration (improving ischaemic neuropathy). Forty-six registered trials investigate efficacy across neuropathy subtypes; eight actively recruit, indicating expanding clinical capacity and commercial interest.
Sunt un candidat? → · Peripheral Neuropathy: full overview → · Cost Neuropatie Periferică → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită